{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:00:38Z","timestamp":1784948438724,"version":"3.55.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.canlet.2024.216900","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T19:53:06Z","timestamp":1713297186000},"page":"216900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules"],"prefix":"10.1016","volume":"591","author":[{"given":"Marta","family":"Banchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Christina","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-9141","authenticated-orcid":false,"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216900_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrc1650","article-title":"Repopulation of cancer cells during therapy: an important cause of treatment failure","volume":"5","author":"Kim","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib4","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-05-0765","article-title":"Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy","volume":"65","author":"Shaked","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib5","first-page":"6938","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib6","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","article-title":"Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy","volume":"100","author":"Bocci","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216900_bib7","article-title":"Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.critrevonc.2011.04.009","article-title":"Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?","volume":"82","author":"Penel","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.216900_bib9","first-page":"1","article-title":"Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy","volume":"107","author":"Sharabi","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1186\/s12885-022-10031-6","article-title":"Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)\/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study","volume":"22","author":"Pepe","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072535","article-title":"Vinorelbine and intermittent cyclophosphamide sensitize an aggressive myc-driven B-cell lymphoma to anti-PD-1 by an immunological memory effective against tumor Re-challenge","volume":"12","author":"Orecchioni","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000807","article-title":"Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma","volume":"8","author":"He","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/0008-5472.CAN-20-1818","article-title":"Cyclophosphamide and vinorelbine activate stem-like CD8(+) T cells and improve anti-PD-1 efficacy in triple-negative breast cancer","volume":"81","author":"Falvo","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ijc.32803","article-title":"Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer","volume":"147","author":"Laheurte","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104995","article-title":"Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma","volume":"25","author":"Webb","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2024.216900_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1017990","article-title":"Reshaping the tumor microenvironment: the versatility of immunomodulatory drugs in B-cell neoplasms","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216900_bib17","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","article-title":"A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib18","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib19","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib20","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2024.216900_bib22","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1200\/JCO.2000.18.16.2935","article-title":"High-time chemotherapy or high time for low dose","volume":"18","author":"Kamen","year":"2000","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2024.216900_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.blre.2004.09.001","article-title":"Follicular lymphoma: time for a re-think?","volume":"19","author":"Gandhi","year":"2005","journal-title":"Blood Rev."},{"key":"10.1016\/j.canlet.2024.216900_bib25","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00277-011-1361-6","article-title":"Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry","volume":"91","author":"Krause","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2024.216900_bib27","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdh384","article-title":"Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity","volume":"15","author":"Rozados","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/cmi.2012.34","article-title":"Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model","volume":"9","author":"Dou","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2024.216900_bib29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20062129","article-title":"Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression","volume":"204","author":"Bopp","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1189\/jlb.0706474","article-title":"Regulatory T cell-mediated suppression: potential role of ICER","volume":"81","author":"Bodor","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.canlet.2024.216900_bib31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","article-title":"Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma","volume":"118","author":"Orecchioni","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib32","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1002\/cam4.2364","article-title":"Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2024.216900_bib33","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"Bolden","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216900_bib34","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/15384047.2016.1250046","article-title":"Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma","volume":"17","author":"Havas","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2024.216900_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13046-016-0327-x","article-title":"Low dose of lenalidmide and PI3K\/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma","volume":"35","author":"Jin","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2141.2010.08367.x","article-title":"Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma","volume":"152","author":"Tucci","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib37","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0277-5379(90)90160-U","article-title":"Chronic daily administration of oral etoposide in refractory lymphoma","volume":"26","author":"Hainsworth","year":"1990","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1200\/JCO.1993.11.7.1322","article-title":"Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I\/II study","volume":"11","author":"Thompson","year":"1993","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00000421-199706000-00022","article-title":"Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin\u2019s lymphoma","volume":"20","author":"Niitsu","year":"1997","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib40","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.1998.16.2.584","article-title":"Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant","volume":"16","author":"Little","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib41","first-page":"1","article-title":"Vinblastine for elderly and frail patients with Hodgkin lymphoma, Leuk","volume":"0","author":"Meynard","year":"2020","journal-title":"Lymphoma"},{"key":"10.1016\/j.canlet.2024.216900_bib42","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/oxfordjournals.annonc.a059010","article-title":"Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease","volume":"5","author":"Devizzi","year":"1994","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.12120","article-title":"Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma","volume":"160","author":"Corazzelli","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2021.10.018","article-title":"Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: the best of two worlds","volume":"524","author":"Cox","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216900_bib46","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/0284186X.2015.1007212","article-title":"A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma","volume":"54","author":"Rueda","year":"2015","journal-title":"Acta Oncol. (Madr)"},{"key":"10.1016\/j.canlet.2024.216900_bib47","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjh.15039","article-title":"Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit","volume":"183","author":"Cox","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s10637-019-00769-5","article-title":"The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma","volume":"37","author":"Cox","year":"2019","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.canlet.2024.216900_bib50","first-page":"841","article-title":"All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma, Cancer Chemother","volume":"86","author":"Cox","year":"2020","journal-title":"Pharmacol."},{"key":"10.1016\/j.canlet.2024.216900_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237162","article-title":"Remarkable remission rate and long-term efficacy of upfront metronomic chemotherapy in elderly and frail patients, with diffuse large B-cell lymphoma","volume":"11","author":"Bocci","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdac105","article-title":"Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis","volume":"4","author":"Batara","year":"2022","journal-title":"Neuro-Oncology Adv"},{"key":"10.1016\/j.canlet.2024.216900_bib53","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib54","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL)","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib56","article-title":"Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib: a case report","author":"Banchi","year":"2023","journal-title":"Chemotherapy"},{"key":"10.1016\/j.canlet.2024.216900_bib57","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104040","article-title":"Revisiting the role of alkylating agents in multiple myeloma: up-to-date evidence and future perspectives","volume":"187","author":"Costa","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.216900_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1218105","article-title":"Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells","volume":"5","author":"Antonangeli","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216900_bib60","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","article-title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","volume":"115","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib61","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib62","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4161\/auto.22866","article-title":"Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells","volume":"9","author":"Cea","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2024.216900_bib63","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","article-title":"Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity","volume":"122","author":"Cagnetta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib64","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2024.216900_bib65","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib66","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib67","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2016.36","article-title":"A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma","volume":"30","author":"Larocca","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216900_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1185991","article-title":"Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications","volume":"13","author":"Shi","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib70","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Van Oekelen","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2024.216900_bib71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/theoncologist.12-1-99","article-title":"Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21","volume":"12","author":"Suvannasankha","year":"2007","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib72","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216900_bib73","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib74","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib75","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib76","doi-asserted-by":"crossref","first-page":"34009","DOI":"10.18632\/oncotarget.26131","article-title":"Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients","volume":"9","author":"Franssen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216900_bib77","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3324\/haematol.2013.085183","article-title":"Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed\/refractory multiple Myeloma","volume":"98","author":"Papanikolaou","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2024.216900_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clml.2021.09.004","article-title":"Treatment bridging with a 28-day metronomic therapy (Metro-28) for relapsed refractory multiple myeloma","volume":"22","author":"Mouhieddine","year":"2022","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"10.1016\/j.canlet.2024.216900_bib79","first-page":"50","article-title":"Continuous low-dose cyclophosphamide - prednisone is effective and well tolerated in patients with advanced multiple myeloma, Neth","volume":"59","author":"De Weerdt","year":"2001","journal-title":"J. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib80","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garc\u00eda-Sanz","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216900_bib81","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.13653","article-title":"Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients","volume":"171","author":"de Waal","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib82","series-title":"Leukemia","author":"Chennamadhavuni","year":"2024"},{"key":"10.1016\/j.canlet.2024.216900_bib83","series-title":"Myelodysplastic Syndrome","author":"Dotson","year":"2024"},{"key":"10.1016\/j.canlet.2024.216900_bib84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib85","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","article-title":"Acute myeloid leukaemia in the elderly: a review","volume":"152","author":"Pollyea","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib86","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib87","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib88","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.seminhematol.2005.05.002","article-title":"Pharmacology of 5-Aza-2\u2019-deoxycytidine (decitabine)","volume":"42","author":"Momparler","year":"2005","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2024.216900_bib89","first-page":"5511","article-title":"Differences in DNA damage produced by incorporation of 5-aza-2\u2019-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells","volume":"46","author":"Covey","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib90","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1093\/nar\/gkm432","article-title":"Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation","volume":"35","author":"Schermelleh","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2024.216900_bib91","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell."},{"key":"10.1016\/j.canlet.2024.216900_bib92","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V64.4.922.922","article-title":"5-Aza-2\u2019-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias","volume":"64","author":"Pinto","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib93","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bcp.2010.10.013","article-title":"Sustained exposure to the DNA demethylating agent, 2\u2019-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy","volume":"81","author":"Schnekenburger","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216900_bib94","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/bjc.1988.298","article-title":"Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia","volume":"58","author":"Richel","year":"1988","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib95","first-page":"53","article-title":"Decitabine in the treatment of acute myeloid leukemia in elderly patients","volume":"6","author":"Malik","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.canlet.2024.216900_bib96","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminoncol.2011.11.011","article-title":"p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies","volume":"39","author":"Saunthararajah","year":"2012","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib97","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1182\/blood-2006-07-035287","article-title":"Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential","volume":"109","author":"Araki","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib98","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/leu.2011.159","article-title":"p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia","volume":"25","author":"Ng","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216900_bib99","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s002800050832","article-title":"Drug resistance to 5-aza-2\u2019-deoxycytidine, 2\u2019,2\u2019-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells","volume":"42","author":"Eliopoulos","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216900_bib100","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.18632\/oncotarget.597","article-title":"High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects","volume":"3","author":"Ebrahem","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216900_bib101","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216900_bib102","article-title":"Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216900_bib103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/cr.2011.152","article-title":"Autophagy: for better or for worse","volume":"22","author":"Wirawan","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2024.216900_bib104","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.leukres.2017.06.007","article-title":"Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells","volume":"60","author":"Chen","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2024.216900_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1258151","article-title":"Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia","volume":"14","author":"Smoljo","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216900_bib106","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib107","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","article-title":"Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD\/SCID\/IL2Rg(null) mice","volume":"131","author":"Cany","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.leu.2402733","article-title":"Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia","volume":"17","author":"Tissing","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216900_bib109","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2006-12-060970","article-title":"Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway","volume":"110","author":"Bornhauser","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib110","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","article-title":"Glycolysis inhibition for anticancer treatment","volume":"25","author":"Pelicano","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216900_bib111","doi-asserted-by":"crossref","first-page":"30978","DOI":"10.18632\/oncotarget.16046","article-title":"Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216900_bib112","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/2278-330X.181644","article-title":"Metronomic therapy with oral 6-mercaptopurine in elderly acute myeloid leukemia: a prospective pilot study","volume":"5","author":"Kapoor","year":"2016","journal-title":"South Asian J. Cancer."},{"key":"10.1016\/j.canlet.2024.216900_bib113","doi-asserted-by":"crossref","first-page":"147","DOI":"10.31557\/APJCP.2020.21.1.147","article-title":"Efficacy and safety of metronomic chemotherapy versus palliative hydroxyurea in unfit acute myeloid leukemia patients: a multicenter, open-label randomized controlled trial","volume":"21","author":"Pongudom","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.canlet.2024.216900_bib114","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12032-024-02302-y","article-title":"Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia","volume":"41","author":"Bouligny","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib115","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib116","first-page":"3874","article-title":"An evaluation of 17 Years of low dose cytarabine as therapy for AML patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy","volume":"130","author":"Dennis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib117","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s002770050569","article-title":"A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes","volume":"79","author":"Venditti","year":"2000","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2024.216900_bib118","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib119","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1182\/bloodadvances.2021005038","article-title":"Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients","volume":"5","author":"Dennis","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.canlet.2024.216900_bib120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clml.2015.11.016","article-title":"Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients","volume":"16","author":"Takahashi","year":"2016","journal-title":"Clin. Lymphoma, Myeloma Leuk"},{"key":"10.1016\/j.canlet.2024.216900_bib121","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jval.2023.09.001","article-title":"Comparative efficacy of venetoclax-based combination therapies and other therapies in treatment-naive patients with acute myeloid leukemia ineligible for intensive chemotherapy: a network meta-analysis","volume":"26","author":"Li","year":"2023","journal-title":"Value Heal. J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"10.1016\/j.canlet.2024.216900_bib122","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.18560","article-title":"A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: results from the LI-1 trial","volume":"200","author":"Mussai","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216900_bib123","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib124","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38414-0","article-title":"Pharmacokinetic-pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia","volume":"13","author":"Gebhard","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.216900_bib126","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib127","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216900_bib128","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/pbc.26139","article-title":"Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?","volume":"63","author":"Schmiegelow","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2015.01.008","article-title":"Metronomic chemotherapy from rationale to clinical studies: a dream or reality?","volume":"95","author":"Gnoni","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.216900_bib130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.canlet.2017.02.027","article-title":"Resistance to metronomic chemotherapy and ways to overcome it","volume":"400","author":"Riesco-Martinez","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216900_bib131","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1593\/neo.101174","article-title":"Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide","volume":"13","author":"Emmenegger","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2024.216900_bib132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10637-013-9974-3","article-title":"Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy","volume":"32","author":"Chow","year":"2014","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.canlet.2024.216900_bib133","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3892\/ijo.2015.3059","article-title":"Metronomic vinorelbine: anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition","volume":"47","author":"Mavroeidis","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib134","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/0008-5472.CAN-05-2598","article-title":"Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia","volume":"66","author":"Emmenegger","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216900_bib135","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ajpath.2011.11.029","article-title":"Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment","volume":"180","author":"Akiyama","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2024.216900_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160094","article-title":"Schedule-dependent antiangiogenic and cytotoxic effects of chemotherapy on vascular endothelial and retinoblastoma cells","volume":"11","author":"Winter","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216900_bib137","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0058","article-title":"Chemotherapy dosing schedule influences drug resistance development in ovarian cancer","volume":"10","author":"De Souza","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2024.216900_bib138","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy","volume":"112","author":"Coleman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib139","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216900_bib140","doi-asserted-by":"crossref","first-page":"e1213","DOI":"10.1016\/S2214-109X(20)30275-8","article-title":"Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial","volume":"8","author":"Patil","year":"2020","journal-title":"Lancet Glob. Heal."},{"key":"10.1016\/j.canlet.2024.216900_bib141","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2024.216900_bib142","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib143","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5483791","article-title":"Metronomic chemotherapy: a systematic review of the literature and clinical experience","volume":"2019","author":"Simsek","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib144","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092236","article-title":"Metronomic chemotherapy","volume":"13","author":"Cazzaniga","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216900_bib145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib146","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib147","first-page":"257","article-title":"Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation, Hematol","volume":"38","author":"Ferreri","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib148","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103010","article-title":"Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis","volume":"152","author":"Hou","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2024.216900_bib150","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib151","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/jjco\/hyab112","article-title":"Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy","volume":"51","author":"Yamauchi","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib152","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216900_bib153","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2021-147802","article-title":"A randomised evaluation of low-dose cytarabine arabinoside plus lenalidomide versus single-agent low-dose cytarabine arabinoside in older patients with acute myeloid leukaemia: results from the LI-1 trial","volume":"138","author":"Copland","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216900_bib154","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10238-020-00666-9","article-title":"Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients","volume":"21","author":"Valenzuela","year":"2021","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216900_bib155","series-title":"Monitoring Minimal Residual Disease in ALL and AML","first-page":"431","author":"Bader","year":"2019"},{"key":"10.1016\/j.canlet.2024.216900_bib156","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216900_bib157","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.1200\/JCO.2022.40.16_suppl.8047","article-title":"Evaluating serum-free light chain ratio as a biomarker for multiple myeloma","volume":"40","author":"Akhlaghi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib158","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216900_bib159","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1038\/sj.onc.1211031","article-title":"Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts","volume":"27","author":"Shahrzad","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216900_bib160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13104-020-05423-5","article-title":"Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial","volume":"14","author":"Phinyo","year":"2021","journal-title":"BMC Res. Notes"},{"issue":"25","key":"10.1016\/j.canlet.2024.216900_bib161","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:16:22Z","timestamp":1784945782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":161,"alternative-id":["S0304383524002933"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216900","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216900"}}